HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Immunotherapies shift research focus from tumor to technique
-
- Raghavan, Sweetenham named HemOnc Today’s Chief Medical Editors
- Chemotherapy plus radiation therapy prolonged OS in low-grade glioma
- 2014 Oncology Drugs in the Pipeline
- FDA approves Cyramza for stomach cancer
- FDA approves Arzerra in combination with chlorambucil for CLL
- Pediatric cancer survivors at increased risk for mortality, morbidity after age 35
- ASCO: SLNB an option for more women with operable breast cancer
- Maintenance rituximab extended PFS, not OS in follicular lymphoma
-
- Mediterranean diet linked to lower platelet, white blood cell counts
- ABCD salvage therapy safe, effective in relapsed multiple myeloma
- Age-based criteria led to colorectal cancer screening misuse
- IMRT improved cause-specific survival in head and neck cancers
- IVC filter reduced PE mortality, increased VTE recurrence
- Music therapy fostered resilience among AYA patients undergoing high-risk cancer treatment Christine A. Zawistowski, MD
- Surgical resection extended OS in huge hepatocellular carcinoma
- Trabectedin demonstrated activity in germline BRCA-mutated breast cancer
-
- Veliparib safe, effective among women with BRCA-mutated gynecologic cancers
- Women demonstrated more favorable outcomes in CLL
- Early symptoms of OPSCC may be tied to HPV status
- Radical prostatectomy reduced early prostate cancer mortality
- Genetic mutation increased risk for lung cancer among women, never-smokers
- Data-sharing project to help answer critical questions in cancer care
- Sentinel-node biopsy improved DFS, staging in melanoma
- FGFR-targeted therapy demonstrated activity in solid tumors
-
- Palbociclib plus letrozole extended PFS in metastatic breast cancer
- PD-L1 expression predicted response to immunotherapy in melanoma
- Vismodegib effective in basal cell carcinoma
- Ipilimumab may become standard of care for adjuvant melanoma therapy
- T-VEC superior to GM-CSF for unresected, metastatic melanoma
- Selumetinib shows promise for patients with recurrent low-grade ovarian cancer Andrea Dickens, PharmD; Allison Walls, PharmD, BCOP